GlassScriptPhysician profile
Lorrie T Cheng
NPI 1528353943
$1,718.85
in general payments reported to CMS, 2019-2025
14 companies · $714 in 2025
The $714 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $396 · 2024: $608 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.37 | 2023-2025 | Lumigan, Alphagan P, Durysta |
| Sun Pharmaceutical Industries INC. | $296.01 | 2023-2025 | Cequa |
| Alcon Vision LLC | $208.85 | 2024-2025 | Tryptyr, Clareon, Hydrus Microstent |
| Rxsight INC | $141.51 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Tarsus Pharmaceuticals, INC. | $85.52 | 2024-2025 | Xdemvy |
| Thea Pharma INC. | $31.34 | 2024-2025 | Iyuzeh |
| Harrow Eye, LLC | $27.16 | 2025 | Vevye |
| Lkc Technologies, INC. | $22.16 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.26 | 2023 | Syfovre |
| Coopervision INC. | $19.33 | 2023 | Myday Contact Lens |
| Oyster Point Pharma, INC. | $17.40 | 2024 | Tyrvaya |
| Dompe US, INC. | $17.27 | 2025 | Oxervate |
| Glaukos Corporation | $15.61 | 2025 | Idosetr |
| Astellas Pharma US INC | $15.06 | 2025 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorrie Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.